Healthcare utilization and costs associated with tyrosine kinase inhibitor switching in patients with chronic myeloid leukemia

References

• Faderl S, Talpaz M, Estrov Z, et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.
   PubMed Web of Science ®Google Scholar
• Van Etten RA, Mauro M, Radich JP, et al. Advances in the biology and therapy of chronic myeloid leukemia: proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia and Myeloproliferative Neoplasms Workshop. Leuk Lymphoma 2013; 54: 1151–1158.
   PubMed Web of Science ®Google Scholar
• Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma 2013; 54: 1411–1417.
   PubMed Web of Science ®Google Scholar
• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9–29.
   PubMed Web of Science ®Google Scholar
• Sawyers CL. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.
   PubMed Web of Science ®Google Scholar
• Alvarez RH, Kantarjian H, Cortes JE. The biology of chronic myelogenous leukemia: implications for imatinib therapy. Semin Hematol 2007; 44(Suppl. 1): S4–S14.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Cortes J, Kantarjian H. Treatment selection after imatinib resistance in chronic myeloid leukemia. Target Oncol 2009; 4: 3–10.
   PubMed Web of Science ®Google Scholar
• O’Brien S, Radich JP, Abboud CN, et al. Clinical practice guidelines: chronic myelogenous leukemia, version 2.2014, National Comprehensive Cancer Network (NCCN). J Natl Comp Cancer Network 2014; 103: 553–561.
   Google Scholar
• Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst 2011; 103: 553–561.
   PubMed Web of Science ®Google Scholar
• O'Brien S, Tefferi A, Valent P. Chronic myelogenous leukemia and myeloproliferative disease. Hematol Am Soc Hematol Educ Program 2004; 1: 146–162.
   Google Scholar
• Quintas-Cardama A, Kantarjian HM, Cortes JE. Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia. Cancer Control 2009; 16: 122–131.
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994–1004.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.
   PubMed Web of Science ®Google Scholar
• Lucas CM, Wang L, Austin GM, et al. A population study of imatinib in chronic myeloid leukaemia demonstrates lower efficacy than in clinical trials. Leukemia 2008; 22: 1963–1966.
   PubMed Web of Science ®Google Scholar
• de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358–3363.
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2010; 362: 2260–2270.
   PubMed Web of Science ®Google Scholar
• Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 2010; 362: 2251–2259.
   PubMed Web of Science ®Google Scholar
• Mauro MJ. Defining and managing imatinib resistance. Hematol Am Soc Hematol Educ Program 2006; 1: 219–225.
   Google Scholar
• Garg RJ, Kantarjian H, O'Brien S, et al. The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up. Blood 2009; 114: 4361–4368.
   PubMed Web of Science ®Google Scholar
• Michallet M, Tulliez M, Corm S, et al. Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study. Curr Med Res Opin 2010; 26: 307–317.
   PubMed Web of Science ®Google Scholar
• Soverini S, Gnani A, Colarossi S, et al. Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. Blood 2009; 114: 2168–2171.
   PubMed Web of Science ®Google Scholar
• Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008; 26: 4806–4813.
   PubMed Web of Science ®Google Scholar
• Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol 2005; 23: 4100–4109.
   PubMed Web of Science ®Google Scholar
• Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.
   PubMed Web of Science ®Google Scholar
• Soverini S, Branford S, Nicolini FE, et al. Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia. Leuk Res 2014; 38: 10–20.
   PubMed Web of Science ®Google Scholar
• Parker WT, Ho M, Scott HS, et al. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood 2012; 119: 2234–2238.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 2009; 23: 1054–1061.
   PubMed Web of Science ®Google Scholar
• O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009; 16: 401–412.
   PubMed Web of Science ®Google Scholar
• Nicolini FE, Khoury HJ, Akard L, et al. Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors. Haematologica 2013; 98: e78–e79.
   PubMed Web of Science ®Google Scholar
• Cortes JE, Nicolini FE, Wetzler M, et al. Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib. Clin Lymphoma Myeloma Leuk 2013; 13: 584–591.
   PubMed Web of Science ®Google Scholar
• Cortes J, Lipton JH, Rea D, et al. Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation. Blood 2012; 120: 2573–2580.
   PubMed Web of Science ®Google Scholar
• Nazha A, Kantarjian H, Cortes J, Quintas-Cardama A. Omacetaxine mepesuccinate (synribo) – newly launched in chronic myeloid leukemia. Expert Opin Pharmacother 2013; 14: 1977–1986.
   PubMed Web of Science ®Google Scholar
• Allan EK, Holyoake TL, Craig AR, et al. Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 2011; 25: 985–994.
   PubMed Web of Science ®Google Scholar
• Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol 2014; 32: 306–311.
   PubMed Web of Science ®Google Scholar
• Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics 2007; 25: 481–496.
   PubMed Web of Science ®Google Scholar
• Aggoune D, Tosca L, Sorel N, et al. Modeling the influence of stromal microenvironment in the selection of ENU-induced BCR-ABL1 mutants by tyrosine kinase inhibitors. Oncoscience 2014; 1: 57–68.
   PubMedGoogle Scholar
• Hirji I, Gupta S, Goren A, et al. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective. Health Qual Life Outcomes 2013; 11: 167.
   PubMed Web of Science ®Google Scholar
• Cella D, Nowinski CJ, Frankfurt O. The impact of symptom burden on patient quality of life in chronic myeloid leukemia. Oncology 2014; 87: 133–147.
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood 2008; 111: 1039–1043.
   PubMed Web of Science ®Google Scholar
• Goldberg SL, Akard LP, Dugan MJ, et al. Barriers to physician adherence to evidence-based monitoring guidelines in chronic myelogenous leukemia. J Oncol Pract 2015; 11: e398–e404.
   PubMed Web of Science ®Google Scholar
• Trask PC, Cella D, Powell C, et al. Health-related quality of life in chronic myeloid leukemia. Leuk Res 2013; 37: 9–13.
   PubMed Web of Science ®Google Scholar
• Trask PC, Cella D, Besson N, et al. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res 2012; 36: 438–442.
   PubMed Web of Science ®Google Scholar
• Guerin A, Chen L, Dea K, et al. Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia. J Med Econ 2014; 17: 89–98.
   PubMedGoogle Scholar